ASTRA Therapeutics SA, a start-up company developing precision drugs against eukaryotic pathogens, announced the successful closing of its CHF 7.75m seed financing round.

The investment was co-led by MIG Capital and Digitalis Ventures, with additional participation from Borealis Ventures, Kickfund and Venture Kick.

VISCHER advised ASTRA Therapeutics SA on all corporate and contractual issues related to this financing round. The team was led by Maxime Chollet (Partner, Corporate/M&A) with Basile Walder (Managing Associate, Corporate/M&A), and further involved Christoph Enz (Associate, Civil Law Notary), Nadia Tarolli (Partner, Tax) and Lukas Henny (Associate, Tax).

Author: Maxime Chollet